Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAT-PKD
NCT07282821Phase 2Recruiting
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Bempedoic Acid with Placebo (2 arms). Primary endpoints: Rate of serious adverse events and adverse events of special interest at 24 months and Drug tolerability at 24 months. Started Sep 2026; status: recruiting.
02
Drugs
bempedoic acid
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT07282821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282821.